Obesity deals come into focus after Roche shells out $2.7B for Carmot
Roche’s $2.7 billion bolt-on deal for Carmot Therapeutics is the latest example of how pharma companies are racing to get back into obesity, drug development’s most prized field, analysts told Endpoints News.
The Monday morning deal came on the heels of Pfizer’s disclosure last Friday that it wouldn’t move its obesity asset, danuglipron, into Phase III testing.
“The news about Pfizer just reiterated the importance of a once-daily oral and making sure that you can achieve the efficacy that you want without necessarily sacrificing the [adverse event] profile,” Carmot CEO Heather Turner told Endpoints News. “Ultimately, that’s what was the challenge with danuglipron.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.